

# Genomics & Data Science: Approaches to identifying key variants through functional impact & recurrence



Mark Gerstein  
Yale


Slides freely  
downloadable from  
[Lectures.GersteinLab.org](http://Lectures.GersteinLab.org)  
& “tweetable”  
(via @MarkGerstein).

No Conflicts for this Talk

See last slide for more info.


# Personal Genomics as a Gateway into Biology



Personal genomes will soon become a commonplace part of medical research & eventually treatment (esp. for cancer). They will provide a primary connection for biological science to the general public.



# Personal Genomics as a Gateway into Biology

Personal genomes will soon become a commonplace part of medical research & eventually treatment (esp. for cancer). They will provide a primary connection for biological science to the general public.





Keys to genome interpretation

Relating individuals' variants to **DBs**



**Scaling** DBs to the **population**

Identifying **key variants** - separating into rare, recurrent, common, &c

# DB Growth: explosion of data scale & a diversity of uses


- The type of sequence data deposited has changed as well.
  - Protected data represents an increasing fraction of all submitted sequences.

## Bases in the SRA




# Sequencing Data Explosion: Faster than Moore's Law?

- In the early 2000's, improvements in Sanger sequencing produced a scaling pattern similar to Moore's law.
- The advent of NGS was a shift to a new technology with dramatic decrease in cost).





# Moore's Law: Exponential Scaling of Computer Technology

- Exponential increase in the number of transistors per chip.
- Led to improvements in speed and miniaturization.
- Drove widespread adoption and novel applications of computer technology.




# Kryder's Law and S-curves underlying exponential growth

- Moore's & Kryder's Laws
  - As important as the increase in computer speed has been, the ability to store large amounts of information on computers is even more crucial
- Exponential increase seen in Kryder's law is a superposition of S-curves for different technologies






# The changing costs of a sequencing pipeline




From '00 to ~'20,  
cost of DNA sequencing expt. shifts  
from the actual seq. to sample  
collection & analysis


# The changing costs of a sequencing pipeline




From '00 to ~'20,  
cost of DNA sequencing expt. shifts  
from the actual seq. to sample  
collection & analysis



# The changing costs of a sequencing pipeline




From '00 to ~'20,  
cost of DNA sequencing expt. shifts  
from the actual seq. to sample  
collection & analysis




Alignment algorithms scaling to keep  
pace with data generation

# The changing costs of a sequencing pipeline




From '00 to ~'20,  
cost of DNA sequencing expt. shifts  
from the actual seq. to sample  
collection & analysis




Alignment algorithms scaling to keep  
pace with data generation


# The changing costs of a sequencing pipeline



From '00 to ~'20,  
cost of DNA sequencing expt. shifts  
from the actual seq. to sample  
collection & analysis



# Human Genetic Variation



\* Variants with allele frequency < 0.5% are considered as rare variants in 1000 genomes project.

# Finding Key Variants

## Germline

**CAN YOU FIND THE PANDA?**



- **Common variants**

- Can be most readily associated with phenotype (ie disease) via GWAS
- Usually their functional effect is weaker
- Many are non-coding
- Issue of LD in identifying the actual causal variant.


- **Rare variants**

- Associations are usually underpowered due to low frequencies but often have larger functional impact
- Can be collapsed in the same element to gain statistical power (burden tests).

## CAN YOU FIND THE PANDA?

# Finding Key Variants

## Somatic



- **Overall**

- Often these can be thought of as very rare variants

- **Drivers**

- Driver mutation is a mutation that directly or indirectly confers a selective growth advantage to the cell in which it occurs.
- A typical tumor contains 2-8 drivers; the remaining mutations are passengers.

- **Passengers**

- Conceptually, a passenger mutation has no direct or indirect effect on the selective growth advantage of the cell in which it occurred.



# Genomics & Data Science:

## Approaches to identifying key variants through functional impact & recurrence

- Introduction
  - An individual's disease variants as the public's gateway into genomics & biology
  - **The exponential scaling** of data generation & processing
  - Mining the data to prioritize variants for key drivers
- Functional impact #1: Coding
  - **ALoFT**: Annotation of Loss-of-Function Transcripts.
  - LoF annotation as a complex problem + finding deleterious LoFs
  - **Frustration** as a localized metric of SNV impact. Differential profiles for oncogenes v. TSGs
- Functional impact #2: Non-coding
  - **FunSeq** integrates evidence, with an entropy based weighting scheme.
  - Prioritizing rare variants with “sensitive sites” (human conserved)
- Recurrence:  
Statistics for driver identification
  - **Background mutation rate** significantly varies & is correlated with replication timing & TADs
  - Developed a variety of parametric & non-parametric methods taking this into account
  - **LARVA** uses parametric beta-binomial model, explicitly modeling covariates
  - **MOAT** does a variety of non-parm. shuffles (annotation, variants, &c). Useful when explicit covariates not available. Slower than but speeded up w/ GPUs

# Genomics & Data Science:

## Approaches to identifying key variants through functional impact & recurrence

- Introduction

- An individual's disease variants as the public's gateway into genomics & biology
- **The exponential scaling** of data generation & processing
- Mining the data to prioritize variants for key drivers

- Functional impact #1: Coding

- **ALoFT**: Annotation of Loss-of-Function Transcripts.
- LoF annotation as a complex problem + finding deleterious LoFs
- **Frustration** as a localized metric of SNV impact. Differential profiles for oncogenes v. TSGs

- Functional impact #2: Non-coding

- **FunSeq** integrates evidence, with an entropy based weighting scheme.
- Prioritizing rare variants with “sensitive sites” (human conserved)

- Recurrence:

### Statistics for driver identification

- **Background mutation rate** significantly varies & is correlated with replication timing & TADs
- Developed a variety of parametric & non-parametric methods taking this into account
- **LARVA** uses parametric beta-binomial model, explicitly modeling covariates
- **MOAT** does a variety of non-parm. shuffles (annotation, variants, &c). Useful when explicit covariates not available. Slower than but speeded up w/ GPUs

# Variant Annotation Tool (VAT), developed for 1000G FIG



VCF Input

Output:

- Annotated VCFs
- Graphical representations of functional impact on transcripts

Access:

- Webserver
- AWS cloud instance
- Source freely available



[vat.gersteinlab.org](http://vat.gersteinlab.org)

Habegger L.<sup>\*</sup>, Balasubramanian S.<sup>\*</sup>, et al. *Bioinformatics*, 2012


# Complexities in LOF annotation

Transcript isoforms,  
distance to stop,  
functional domains,  
protein folding,  
etc.


Balasubramanian S. et al., *Genes Dev.*, '11

Balasubramanian S.\*, Fu Y.\* et al., *NComms.*, '17


## Impact of a SNP on alternate splice forms



1KG



HGMD




# Annotation of Loss-of-Function Transcripts (ALoFT)

Runs on top of VAT



Output:

- Impact score: benign or deleterious.
- Decorated VCF.

Balasubramanian S.\* , Fu Y.\* et al., *NComms.*, '17





# LoF distribution varies as expected by mutation set (from healthy people v from disease)



Balasubramanian S.\*, Fu Y.\* et al., *NComms.*, '17

# Application to LoF mutations in autism spectrum disorder



Balasubramanian S.\*, Fu Y.\* et al., NComms., '17

# ALoFT identifies deleterious somatic LoF variants

## Cancer genes:


- COSMIC consensus.
- *Enriched in deleterious LoFs.*

## LoF tolerant genes:

- LoF in the 1KG cohort.
- *Depleted in deleterious LoFs.*


## cancer genes vs. LoF tolerant genes

- 504 cancer genes
- 387 LoF-tolerant genes
- 504 random genes
- 387 random genes







# ALoFT refines cancer mutation characterization



Vogelstein *et al.* '13: if >20% of mutations in gene inactivating → tumor suppressor gene (TSG).

ALoFT further refines 20/20 rule predictions.



# Genomics & Data Science:

## Approaches to identifying key variants through functional impact & recurrence

- Introduction

- An individual's disease variants as the public's gateway into genomics & biology
- **The exponential scaling** of data generation & processing
- Mining the data to prioritize variants for key drivers

- Functional impact #1: Coding

- **ALoFT**: Annotation of Loss-of-Function Transcripts.
- LoF annotation as a complex problem + finding deleterious LoFs
- **Frustration** as a localized metric of SNV impact. Differential profiles for oncogenes v. TSGs



- Functional impact #2: Non-coding

- **FunSeq** integrates evidence, with an entropy based weighting scheme.
- Prioritizing rare variants with “sensitive sites” (human conserved)

- Recurrence:


### Statistics for driver identification

- **Background mutation rate** significantly varies & is correlated with replication timing & TADs
- Developed a variety of parametric & non-parametric methods taking this into account
- **LARVA** uses parametric beta-binomial model, explicitly modeling covariates
- **MOAT** does a variety of non-parm. shuffles (annotation, variants, &c). Useful when explicit covariates not available. Slower than but speeded up w/ GPUs




What is localized frustration ?


# Workflow for evaluating localized frustration changes ( $\Delta F$ )



# Complexity of the second order frustration calculation




# Comparing $\Delta F$ values across different SNV categories: disease v normal



Normal mutations (1000G) tend to unfavorably frustrate (less frustrated) surface more than core, but for disease mutations (HGMD) no trend & greater changes

# Comparison between $\Delta F$ distributions: TSGs v. oncogenes



SNVs in TSGs change frustration more in core than the surface, whereas those associated with oncogenes manifest the opposite pattern. This is consistent with differences in LOF v GOF mechanisms.

# Genomics & Data Science:

## Approaches to identifying key variants through functional impact & recurrence

- Introduction
  - An individual's disease variants as the public's gateway into genomics & biology
  - **The exponential scaling** of data generation & processing
  - Mining the data to prioritize variants for key drivers
- Functional impact #1: Coding
  - **ALoFT**: Annotation of Loss-of-Function Transcripts.
  - LoF annotation as a complex problem + finding deleterious LoFs
  - **Frustration** as a localized metric of SNV impact. Differential profiles for oncogenes v. TSGs
- Functional impact #2: Non-coding
  - **FunSeq** integrates evidence, with an entropy based weighting scheme.
  - Prioritizing rare variants with “sensitive sites” (human conserved)
- Recurrence:  
Statistics for driver identification
  - **Background mutation rate** significantly varies & is correlated with replication timing & TADs
  - Developed a variety of parametric & non-parametric methods taking this into account
  - **LARVA** uses parametric beta-binomial model, explicitly modeling covariates
  - **MOAT** does a variety of non-parm. shuffles (annotation, variants, &c). Useful when explicit covariates not available. Slower than but speeded up w/ GPUs




# Funseq: a flexible framework to determine functional impact & use this to prioritize variants

Annotation (tf binding sites open chromatin, ncRNAs) & Chromatin Dynamics

Conservation (GERP, allele freq.)


Mutational impact (motif breaking, Lof)

Network (centrality position)



# Finding "Conserved" Sites in the Human Population:


Negative selection in non-coding elements based on  
Production ENCODE & 1000G Phase 1



Broad categories of  
regulatory regions under  
negative selection  
Related to:



ENCODE, *Nature*, 2012  
Ward & Kellis, *Science*, 2012  
Mu et al, *NAR*, 2011

# Differential selective constraints among specific sub-categories



Sub-categorization possible because of better statistics from 1000G phase 1 v pilot

[Khurana et al., *Science* ('13)]




Sub-categorization possible because of better statistics from 1000G phase 1 v pilot

# Defining Sensitive non-coding Regions



Start **677** high-resolution non-coding categories; Rank & find those under strongest selection

[Khurana et al., *Science* ('13)]

# SNPs which break TF motifs are under stronger selection



[Khurana et al., *Science* ('13)]



Genome





$$w_d = 1 + p_d \log_2 p_d + (1 - p_d) \log_2 (1 - p_d)$$

- Entropy based method for weighting consistently many genomic features
- Practical web server
- Submission of variants & pre-computed large data context from uniformly processing large-scale datasets

**Legend:**

- Process (Red box)
- Pre-collected data (Yellow folder icon)
- User-optional input (Green circle icon)
- User-specific input/output (Hatched oval icon)




# Germline pathogenic variants show higher core scores than controls



3 controls with natural polymorphisms (allele frequency  $\geq 1\%$  )

1. Matched region: 1kb around HGMD variants
2. Matched TSS: matched for distance to TSS
3. Unmatched: randomly selected

# Flowchart for 1 Prostate Cancer Genome (from Berger et al. '11)



[Khurana et al., Science ('13)]




# Genomics & Data Science:


## Approaches to identifying key variants through functional impact & recurrence

- Introduction
  - An individual's disease variants as the public's gateway into genomics & biology
  - **The exponential scaling** of data generation & processing
  - Mining the data to prioritize variants for key drivers
- Functional impact #1: Coding
  - **ALoFT**: Annotation of Loss-of-Function Transcripts.
  - LoF annotation as a complex problem + finding deleterious LoFs
  - **Frustration** as a localized metric of SNV impact. Differential profiles for oncogenes v. TSGs
- Functional impact #2: Non-coding
  - **FunSeq** integrates evidence, with an entropy based weighting scheme.
  - Prioritizing rare variants with “sensitive sites” (human conserved)
- Recurrence:  
Statistics for driver identification
  - **Background mutation rate** significantly varies & is correlated with replication timing & TADs
  - Developed a variety of parametric & non-parametric methods taking this into account
  - **LARVA** uses parametric beta-binomial model, explicitly modeling covariates
  - **MOAT** does a variety of non-parm. shuffles (annotation, variants, &c). Useful when explicit covariates not available. Slower than but speeded up w/ GPUs


# Mutation recurrence




# Mutation recurrence





# Noncoding annotations





# Noncoding annotations



# Cancer Somatic Mutational Heterogeneity, across cancer types, samples & regions




1 Mbp genome regions (locations chosen at random)



Chromatin remodeling failure leads to more mutations in early-replicating regions

**Variation in somatic mutations is closely associated with chromatin structure (TADs) & replication timing**

# mrTADFinder: Identifying TADs at multiple resolutions by maximizing modularity vs appropriate null




Choose a particular resolution  $\gamma$   
Optimize Q over all possible partitions

$$Q = \frac{1}{2N} \sum_{ij} (W_{ij} - \gamma E_{ij}) \delta_{\sigma_i \sigma_j} \quad \gamma: \text{resolution parameter}$$

Multiple runs to define boundary scores  
for all pairs of adjacent bins

consensus boundaries based on  
the boundary scores

consensus TADs output



[Yan et al., *PLOS Comp. Bio.* ('17)]



# Genomics & Data Science:

## Approaches to identifying key variants through functional impact & recurrence

- Introduction

- An individual's disease variants as the public's gateway into genomics & biology
- **The exponential scaling** of data generation & processing
- Mining the data to prioritize variants for key drivers

- Functional impact #1: Coding

- **ALoFT**: Annotation of Loss-of-Function Transcripts.
- LoF annotation as a complex problem + finding deleterious LoFs
- **Frustration** as a localized metric of SNV impact. Differential profiles for oncogenes v. TSGs

- Functional impact #2: Non-coding

- **FunSeq** integrates evidence, with an entropy based weighting scheme.
- Prioritizing rare variants with “sensitive sites” (human conserved)

- Recurrence:

### Statistics for driver identification

- **Background mutation rate** significantly varies & is correlated with replication timing & TADs
- Developed a variety of parametric & non-parametric methods taking this into account
- **LARVA** uses parametric beta-binomial model, explicitly modeling covariates
- **MOAT** does a variety of non-parm. shuffles (annotation, variants, &c). Useful when explicit covariates not available. Slower than but speeded up w/ GPUs

# Cancer Somatic Mutation Modeling

## PARAMETRIC MODELS

### Model 1: Constant Background Mutation Rate (Model from Previous Work)

$$x_i : \text{Binomial}(n_i, p)$$

### Model 2a: Varying Mutation Rate with Single Covariate Correction

$$x_i : \text{Binomial}(n_i, p_i)$$

$$p_i : \text{Beta}(\mu | R_i, \sigma | R_i)$$

$\mu | R_i, \sigma | R_i$  : constant within the same covariate rank

### Model 2b: Varying Mutation Rate with Multiple Covariate Correction

$$x_i : \text{Binomial}(n_i, p_i)$$

$$p_i : \text{Beta}(\mu | R_i, \sigma | R_i)$$

$\mu | R_i, \sigma | R_i$  : constant within the same covariate rank

- Suppose there are  $k$  genome elements. For element  $i$ , define:
  - $n_i$ : total number of nucleotides
  - $x_i$ : the number of mutations within the element
  - $p$ : the mutation rate
  - $R_i$ : the covariate rank of the element
- Non-parametric model is useful when covariate data is missing for the studied annotations
  - Also sidesteps issue of properly identifying and modeling every relevant covariate (possibly hundreds)

## NON-PARAMETRIC MODELS

Assume constant background mutation rate in local regions.

### Model 3a: Random Permutation of Input Annotations


Shuffle annotations within local region to assess background mutation rate.

### Model 3b: Random Permutation of Input Variants

Shuffle variants within local region to assess background mutation rate.


[Lochovsky et al. *Bioinformatics* in press]

# MOAT-a: Annotation-based permutation




# MOAT-v: Variant-based Permutation

Can preserve tri-nt context in shuffle




# MOAT-s: a variant on MOAT-v

- A somatic variant simulator
  - Given a set of input variants, shuffle to new locations, taking genome structure into account







# LARVA Model Comparison

- Comparison of mutation count frequency implied by the binomial model (model 1) and the beta-binomial model (model 2) relative to the empirical distribution
- The beta-binomial distribution is significantly better, especially for accurately modeling the over-dispersion of the empirical distribution



# LARVA Results



# MOAT: recapitulates LARVA with GPU-driven runtime scalability

Gene Name	Documented role with cancer	Pubmed ID
SLC3A1	Cysteine transporter SLC3A1 promotes breast cancer tumorigenesis	28382174
ADRA2B	reduce cancer cell proliferation, invasion, and migration	25026350
SIL1	subtype-specific proteins in breast cancer	23386393
TCF24	NA	NA
AGAP5	significant mutation hotspots in cancer	25261935
TMPRSS13	Type II transmembrane serine proteases in cancer and viral infections	19581128
ERO1L	Overexpression of ERO1L is Associated with Poor Prognosis of Gastric Cancer	26987398

⋮

MOAT's high mutation burden elements recapitulate LARVA's results & published noncoding cancer-associated elements.

Computational efficiency of MOAT's NVIDIA™ CUDA™ version, with respect to the number of permutations, is dramatically enhanced compared to CPU version.

Number of permutations	Fold speedup of CUDA version
1k	14x
10k	100x
100k	256x



# Genomics & Data Science:

## Approaches to identifying key variants through functional impact & recurrence

- Introduction

- An individual's disease variants as the public's gateway into genomics & biology
- **The exponential scaling** of data generation & processing
- Mining the data to prioritize variants for key drivers

- Functional impact #1: Coding

- **ALoFT**: Annotation of Loss-of-Function Transcripts.
- LoF annotation as a complex problem + finding deleterious LoFs
- **Frustration** as a localized metric of SNV impact. Differential profiles for oncogenes v. TSGs

- Functional impact #2: Non-coding

- **FunSeq** integrates evidence, with an entropy based weighting scheme.
- Prioritizing rare variants with “sensitive sites” (human conserved)

- Recurrence:

### Statistics for driver identification

- **Background mutation rate** significantly varies & is correlated with replication timing & TADs
- Developed a variety of parametric & non-parametric methods taking this into account
- **LARVA** uses parametric beta-binomial model, explicitly modeling covariates
- **MOAT** does a variety of non-parm. shuffles (annotation, variants, &c). Useful when explicit covariates not available. Slower than but speeded up w/ GPUs

# Genomics & Data Science:

## Approaches to identifying key variants through functional impact & recurrence

- Introduction
  - An individual's disease variants as the public's gateway into genomics & biology
  - **The exponential scaling** of data generation & processing
  - Mining the data to prioritize variants for key drivers
- Functional impact #1: Coding
  - **ALoFT**: Annotation of Loss-of-Function Transcripts.
  - LoF annotation as a complex problem + finding deleterious LoFs
  - **Frustration** as a localized metric of SNV impact. Differential profiles for oncogenes v. TSGs
- Functional impact #2: Non-coding
  - **FunSeq** integrates evidence, with an entropy based weighting scheme.
  - Prioritizing rare variants with “sensitive sites” (human conserved)
- Recurrence:  
Statistics for driver identification
  - **Background mutation rate** significantly varies & is correlated with replication timing & TADs
  - Developed a variety of parametric & non-parametric methods taking this into account
  - **LARVA** uses parametric beta-binomial model, explicitly modeling covariates
  - **MOAT** does a variety of non-parm. shuffles (annotation, variants, &c). Useful when explicit covariates not available. Slower than but speeded up w/ GPUs

github.com/gersteinlab/**Frustration**

S **Kumar**, D Clarke

github.com/gersteinlab/**MrTADfinder**

KK **Yan**, S Lou

**VAT**.gersteinlab.org

L **Habegger**, S Balasubramanian,  
DZ Chen, E Khurana, A Sboner,  
A Harmanci, J Rozowsky, D Clarke, M Snyder

**ALoFT**.gersteinlab.org

S **Balasubramanian**,

Y **Fu**, M Pawashe, P McGillivray,  
M Jin, J Liu, K Karczewski, D MacArthur

**FunSeq**.gersteinlab.org

Y **Fu**, E **Khurana**, Z Liu,  
S Lou, J Bedford, XJ Mu, KY Yip

Acknowledgments

Hiring Postdocs. See

**Jobs**.gersteinlab.org

**CostSeq2**

P **Muir**, S Li, S Lou, D Wang, DJ Spakowicz, L  
Salichos, J Zhang, GM Weinstock, F Isaacs, J  
Rozowsky

**LARVA**.gersteinlab.org

L **Lochovsky**, J **Zhang**,  
Y Fu, E Khurana

**MOAT**.gersteinlab.org

L **Lochovsky**, J **Zhang**

# Info about this talk

## General PERMISSIONS

- This Presentation is copyright Mark Gerstein, Yale University, 2016.
- Please read permissions statement at **[gersteinlab.org/misc/permissions.html](http://gersteinlab.org/misc/permissions.html)** .
- Feel free to use slides & images in the talk with PROPER acknowledgement (via citation to relevant papers or link to gersteinlab.org). Paper references in the talk were mostly from Papers.GersteinLab.org.

## PHOTOS & IMAGES

For thoughts on the source and permissions of many of the photos and clipped images in this presentation see [streams.gerstein.info](http://streams.gerstein.info) . In particular, many of the images have particular EXIF tags, such as `kwpotppt` , that can be easily queried from flickr, viz: [flickr.com/photos/mbgmbg/tags/kwpotppt](https://www.flickr.com/photos/mbgmbg/tags/kwpotppt)